ArticleTargeted oncology2012
Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.
Article in Targeted oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 76 citations in OpenAlex.
- The chimeric aptamer axl-miR-214sponge inhibits breast cancer and melanoma dissemination.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Exosomes in diagnostic and therapeutic applications of ovarian cancer.Journal of ovarian research · 2024Review
- Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.Cancers · 2023Review
- The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.Health science reports · 2023Article
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.Genes & diseases · 2022Review
- Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.Cancers · 2022Review
- LncRNA HOTAIR Promotes Chemoresistance by Facilitating Epithelial to Mesenchymal Transition through miR-29b/PTEN/PI3K Signaling in Cervical Cancer.Cells, tissues, organs · 2022Article
- Aptamer Nanomaterials for Ovarian Cancer Target Theranostics.Frontiers in bioengineering and biotechnology · 2022Review
- Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer.Theranostics · 2022Review
- Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.Clinical epigenetics · 2021Article
- Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.Journal of ovarian research · 2020Article
- Review
- Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b.Cancer cell international · 2020Article
- Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy.Journal of Cancer · 2020Review
- Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells.OncoTargets and therapy · 2020Article
- Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression.International journal of biological sciences · 2020Article
- Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities.International journal of environmental research and public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer has a poor prognosis and advanced ovarian cancer lacks effective therapy. In this study, we seek to establish targeting therapy for ovarian cancer through tumor tissue-specific delivery of miRNA-29b to reexpress PTEN tumor-suppressor gene. A chimera (Chi-29b) was constructed to compose of a mucin 1 (MUC1) aptamer targeting tumor cell surface MUC1 protein and miR-29b inhibiting DNA methyltransferases' expression, subsequently reexpressing PTEN gene. The specificity and efficacy of the chimera delivery were analyzed in OVCAR-3 ovarian tumor cells, and the biological activities of the chimera were identified by the expression of its downstream molecules and cell apoptosis. We demonstrated that Chi-29b chimera can be specifically delivered into OVCAR-3 cells in a concentration-dependent manner. Dicer efficiently cleaved the Chi-29b chimera to release miR-29b. Chi-29b chimera downregulated Dnmt1, Dnmt3a, and Dnmt3b protein levels; induced hypomethylation in PTEN promoter; and upregulated PTEN mRNA and protein expression in OVCAR-3 cells. Importantly, Chi-29b chimera significantly induced apoptosis in OVCAR-3 cells. Our study indicated that Chi-29b chimera can effectively exert antitumor effect through specific delivery of miR-29b into OVCAR-3 tumor cells, subsequently reexpressing PTEN gene and inducing cell apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.